Nano-​cuprous oxide catalyzed one-​pot synthesis of a carbazole-​based STAT3 inhibitor: a facile approach via intramolecular C-​N bond formation reactions by Baburajeev, C.P. et al.
www.rsc.org/advances
RSC Advances
This is an Accepted Manuscript, which has been through the 
Royal Society of Chemistry peer review process and has been 
accepted for publication.
Accepted Manuscripts are published online shortly after 
acceptance, before technical editing, formatting and proof reading. 
Using this free service, authors can make their results available 
to the community, in citable form, before we publish the edited 
article. This Accepted Manuscript will be replaced by the edited, 
formatted and paginated article as soon as this is available.
You can find more information about Accepted Manuscripts in the 
Information for Authors.
Please note that technical editing may introduce minor changes 
to the text and/or graphics, which may alter content. The journal’s 
standard Terms & Conditions and the Ethical guidelines still 
apply. In no event shall the Royal Society of Chemistry be held 
responsible for any errors or omissions in this Accepted Manuscript 
or any consequences arising from the use of any information it 
contains. 
View Article Online
View Journal
This article can be cited before page numbers have been issued, to do this please use:  S. Basappa, P. C.
Baburajeev, C. D. Mohan, G. S. Patil, S. Rangappa, V. Pandey, A. Sebastian, J. Fuchs, A. Bender, P. Lobie
and K. S. Rangappa, RSC Adv., 2016, DOI: 10.1039/C6RA01906D.
Nano-cuprous oxide catalyzed one-pot synthesis of carbazole-based STAT3 inhibitor: A 
facile approach via intramolecular C-N bond formation reactions 
Baburajeev C P,a Chakrabhavi Dhananjaya Mohan,b Govindagouda S. Patil,c Shobith 
Rangappa,d Vijay Pandey,e Anusha Sebastian,a Julian E. Fuchs,f Andreas Bender,f Peter E. 
Lobie,e Basappa,a,* Kanchugarakoppal S. Rangappab,* 
a
Laboratory of Chemical Biology, Department of Chemistry, Bangalore University, Central 
College Campus, Palace Road, Bangalore 560001, India 
b
Department of Studies in Chemistry, Manasagangotri, University of Mysore, Mysore 
570006, India 
c
Bal pharma Ltd, No61-B, Bommasandra, Anekal Taluk, Bangalore 560099 
d
Frontier Research Center for Post-Genome Science and Technology, Hokkaido University, 
Sapporo 060-0808, Japan 
e
Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599 
f
Centre for Molecular Informatics, Department of Chemistry, University of Cambridge, 
Lensfield Road, Cambridge, United Kingdom 
 
*Corresponding Authors 
Abstract 
In this study, we report the one-pot synthesis of substituted carbazole derivatives using nano 
cuprous oxide as a catalyst via intramolecular C-N bond forming reactions. Among the 
synthesized carbazoles, 3'-((3-acetyl-6-chloro-9H-carbazol-9-yl)methyl)-[1,1'-biphenyl]-2-
carbonitrile (ACB) was identified as lead antiproliferative agent against lung cancer cell lines 
A549 and LLC with an IC50 of 13.6 and 16.4 µM respectively. Further, we found that lead 
compound suppresses the constitutive phosphorylation of STAT3 (Tyr-705) in A549, HCC-
2279 and H1975 cells. We analyzed the levels of phospho-STAT3 and LSD1 in the nuclear 
extract of ACB treated HCC-2279 cells to evaluate the transcriptional activity of STAT3. We 
found the downregulation of phospho-STAT3 without any change in the expression of LSD1 
indicating that ACB downregulates the transcriptional activity of STAT3. Molecular docking 
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analysis revealed that ACB makes favorable interaction with Arg-609 and Ser-613 in pTyr 
site of SH2 domain of STAT3. 
Introduction 
Signal transducer and activator of transcription (STAT) proteins are originally 
identified as inducible transcription factors in the context of cytokine signaling two decades 
ago.1, 2 STAT1, 2, 3, 4, 5a, 5b and 6 are the seven members of STAT family and STAT3 
being persistently activated in several types of cancers.3, 4 In an unstimulated cell, STAT3 
remains as monomer in the cytoplasm and on stimulation of upstream receptors with various 
ligands including cytokines and growth factors leads to the phosphorylation of STAT3 
(Y705) following dimerization and translocation into nucleus to transcribe STAT3 target 
genes.5, 6 Various proliferative, angiogenic, survival, pro-inflammatory, antiapoptotic, 
metastatic proteins including, cyclin D1, HIF-1α, VEGF, Bcl-2, MMPs, COX-2 and 
RANTES are regulated by JAK-STAT3 signaling contributing to tumorigenesis.7-9 Studies 
have revealed that, blockade of STAT3 signaling by natural/synthetic small molecules and 
RNA interference significantly decrease the cell survival and antiapoptosis of cancer cells.10, 
11 
Carbazole was initially isolated in 1872 by Graebe and Glazer.12 The natural occurrence and 
medicinal properties of carbazole was demonstrated after the discovery of murrayanine, a 
carbazole derived alkaloid from Murraya koenigii Spreng in 1964.13, 14 Since then several 
natural sources have been identified for the presence of carbazole derivatives including blue-
green algae, Aspergillus species and Actinomadura species. Furthermore, carbazoles have 
been shown to induce their anticancer effect in various cancer models by inhibiting wide 
array of targets.15-19 BC3EE2,9B and KPYB10602 are the synthetic carbazole derivatives 
which have been reported to possess good antioncogenic property in several types of cancer 
cells. BC3EE2,9B was reported to upregulate autophagy and synergistically sensitizes human 
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glioblastoma cells to temozolomide.20 KPYB10602, a lactam-fused carbazole derivative and 
inhibitor of kinesin spindle protein, induced anticancer activity in human ovarian cancer cells 
and in vivo tumor model.21 Furthermore, various novel carbazole derivatives were reported to 
downregulate the phosphorylation of STAT322, 23 and effectively inhibiting the in vivo growth 
of human TNBC and lung tumor xenografts.24 Therefore, carbazole has been identified as a 
privileged scaffold in medicinal chemistry for the development of therapeutics against cancer.   
Several research groups have reported the synthesis of carbazoles using various synthetic 
strategies.25-27 The development of mild and efficient protocol for the preparation of 
carbzoles remains as a challenge for researchers in synthetic organic chemistry. In 
continuation of our effort to develop synthetic small molecules and explore their 
pharmacological properties,28-32 herein, we report the one-pot synthesis of substituted 
carbazole derivatives using nano cuprous oxide as a catalyst via intramolecular C-N bond 
forming reactions. The advantage of this method lies in the fact that N-alkylation and C-N 
bond formation takes simultaneously and eventually resulted in one-pot synthesis of title 
compounds. In addition, we identified 3'-((3-acetyl-6-chloro-9H-carbazol-9-yl)methyl)-[1,1'-
biphenyl]-2-carbonitrile (ACB) as lead cytotoxic agent against lung cancer cells. Further, 
ACB was demonstrated to induce cytotoxicity in cancer cells by modulating the 
transcriptional activity of STAT3 and molecular docking analysis revealed that ACB makes 
favorable interaction with Arg-609 and Ser-613 in pTyr site of SH2 domain of STAT3. 
Experimental Section 
Materials and Method 
All chemicals used were purchased from Sigma-Aldrich. 1H and 13C NMR spectra were 
recorded on a Bruker WH-200 (400MHz) spectrometer in CDCl3 or DMSO-d6 as solvent, 
using TMS as an internal standard and chemical shifts are expressed as ppm. High resolution 
mass spectra were determined on a WATERS Q-TOF Premier-HAB213 instrument, mass 
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spectra were determined on a Agilent LC-MS and the elemental analyses were carried out 
using an Elemental Vario Cube CHNS rapid Analyzer. The progress of the reaction was 
monitored by TLC pre-coated silica gel G plates. Lung cancer cell lines cultured as described 
previously.33 pSTAT3 (Y705), STAT3, β-Actin antibodies and LSD1 (sc-271720) were 
purchased from Santa Cruz, USA. 
Typical procedure for the synthesis of 1-(2'-amino-5',6-dichloro-[1,1'-biphenyl]-3-
yl)ethanone (1a) 
To a solution of 1-(3-bromo-4-chlorophenyl) ethanone (700 mg, 0.3 mmol) in 10 ml of 
distilled water in a sealed tube, (2-(2-amino-5-chlorophenyl)-4,5,5-trimethyl-1,3,2-
dioxaborolan-4-yl)methylium (0.32 mmol), SCS-Bi2O3 (0.24 mmol), TBAB (0.15 mmol) and 
[1,1′Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.009 mmol) was added and the 
reaction mixture was heated to 110 °C for the required time. The reaction was cooled to room 
temperature and filtered to remove the base and catalyst. The product was extracted from the 
water layer by thrice in ethyl acetate (5 ml), dried with magnesium sulfate, filtered, and 
concentrated in vacuum. The crude product was purified by recrystallization using ethanol. 
The yield of the obtained product (1a) was 85 % (714 mg). 
Typical procedure for the synthesis of 2',5-dichloro-5'-ethyl-[1,1'-biphenyl]-2-amine 
(1b) 
To a mixture of (1a) (500 mg, 3 mmol) in tetrahydrofuran (5 ml), sodiumborohydride 
(NaBH4) (6 mmol), boron trifluoride diethyletherate (BF3 Etherate) (6 mmol) was added at 10 
ºC-15 ºC. The reaction mass was stirred at room temperature for 10-12 h and completion of 
the reaction was monitored by TLC. 1 ml of dil. suphuric acid was added and the pH is 
adjusted to 7.5 using 50 % sodium hydroxide solution. The product (1b) is extracted with 
dichloromethane, dried and concentrated. The yield of the obtained product (1b) was 89 % 
(426 mg). 
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Typical procedure for the synthesis of 1-(2'-amino-5',6-dichloro-[1,1'-biphenyl]-3-
yl)ethanol   (1c) 
To a solution of 1a (500 mg, 3 mmol) in ethanol (10 ml), 14 N sodium hydroxide (5 ml) 
NaBH4 (6 mmol) was added lot-wise at 10 ºC-15 ºC. The resulting mixture was stirred at 
room temperature for 10-12 h and completion of the reaction was monitored by TLC. Upon 
the completion of reaction, excess NaBH4 was removed by dil. hydrochloric acid and the 
solvent was concentrated under reduced pressure. The residue was diluted with water (8 ml) 
then extracted with dichloromethane, dried and concentrated to obtain solid product (1c) with 
the yield of 90% (453mg). 
General procedure for copper-catalyzed intramolecular C-N bond-formation reaction 
A reaction flask was charged with substrate 1a-c (1 mmol), 2a-e (1 mmol), DMEDA (0.1 
mmol), Cu2O (8 mol%), and K2CO3 (3 mmol) followed by reagent grade DMF (5 ml). The 
reaction mixture was heated to 150 oC for 15 h. After completion of the reaction, mixture is 
cooled to room temperature, quenched with water and diluted with ethyl acetate (10 ml) and 
the aqueous layer was extracted with  ethyl acetate (3 ml). The combined organic layer was 
washed with water (5 ml), dried over anhydrous sodium sulfate and the solvent was removed 
in vacuum.  The crude product was purified using silica gel column chromatography. All the 
new compounds exhibited spectral properties consistent with the assigned structures and were 
fully characterized by their spectroscopic data (1H, IR, Mass, elemental and 13C NMR 
analysis). 
1-(2'-amino-5',6-dichloro-[1,1'-biphenyl]-3-yl)ethanone (1a)  
Pale yellow colored solid; 1H NMR (400 MHz, DMSO-d6) 8.12 (s, 1H), 8.09-8.07 (d, J=8Hz, 
1H), 7.89 (s, 1H), 7.60-7.58 (d, J=8Hz 1H), 7.38-7.36 (d, J=8Hz, 1H), 7.28-7.25 (d, J=8.0 Hz, 
1H), 5.55 (s, 2H), 2.67 (s, 3H); 13C NMR (100 MHz, DMSO-d6); 198.2, 140.2, 140.1, 135.2, 
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127.2, 125.6, 123.9, 123.3, 121.1, 119.3, 113.4, 112.1, 27.4; HRMS Calcd 302.0110; Found: 
302.0113 (M+Na+). 
2',5-dichloro-5'-ethyl-[1,1'-biphenyl]-2-amine (1b)   
White colored solid; 1H NMR (400 MHz, DMSO-d6) 8.02 (s, J=8 Hz, 1H), 7.89-7.87 (d, J=8 
Hz,1H), 7.70 (s, 1H), 7.55- 7.54 (m, 1H), 7.30-7.16 (m, 2H), 5.68 (s, 2H), 2.81-2.78 (m, 2H), 
1.25-1.22 (m, 2H); 13C NMR (100 MHz, DMSO-d6); 140.8, 138.9,137.9,137.3, 128.9, 127.8, 
127.3, 126.2, 124.0, 123.5, 121.1, 120.99, 22.9, 14.04; LCMS (MM:ES+APCI) 266.4 
(M+H)+; Anal. Calcd for C14H13Cl2N: C, 63.17; H, 4.92; N, 5.26;  Found: C, 63.19; H, 5.29; 
N, 5.28. 
1-(2'-amino-5',6-dichloro-[1,1'-biphenyl]-3-yl)ethanol (1c)  
Off-white colored solid; 1H NMR (400 MHz, DMSO-d6) 7.99 (s, 1H), 7.96-7.94 (d, J=8Hz, 
1H), 7.56 (s, 1H), 7.42- 7.22 (m, 2H), 7.08-7.06 (d, J=8Hz, 1H), 5.54 (s, 2H), 4.94-4.88 (m, 
1H), 4.48-4.35 (m, 1H), 1.28-1.25 (d, 3H); 13C NMR (100 MHz, DMSO-d6); 142.9, 141.2, 
138.6, 125.1, 124.3, 123.1, 120.9, 120.0, 119.8, 112.6, 110.3, 70.0, 29.2; LCMS 
(MM:ES+APCI) 282.4 (M+H)+; Anal. Calcd for C14H13Cl2No: C, 59.59; H, 4.64; N, 4.96;  
Found: C, 60.60; H, 4.65; N, 4.98. 
1-(9-benzyl-6-chloro-9H-carbazol-3-yl)ethanone (3a)  
182 mg (79 %) as yellow colored solid; 1H NMR (400 MHz, DMSO-d6); 8.41 (s, 1H), 8.38-
8.36 (d, J=8Hz, 1H), 8.29 (s, 1H), 7.87-7.85 (dd, J1=4Hz, J2 =4Hz, 1H), 7.72-7.70 (d, J=8Hz, 
1H), 7.54-7.52 (m, 1H), 7.29-7.22 (m, 3H), 7.15-7.14 (m, 2H), 5.80 (s, 2H), 2.68 (s, 3H); 13C 
NMR (100 MHz,  DMSO-d6); 198.3, 140.7, 140.5, 137.8, 135.5, 129.1, 127.8, 127.5, 127.0, 
125.4, 124.5, 123.2, 121.4, 119.9, 112.1, 110.6, 46.2, 27.5; HRMS Calcd 356.0813; Found: 
356.0815 (M+Na+).  
1-(6-chloro-9-(2,6-dichlorobenzyl)-9H-carbazol-3-yl)ethanone (3b) 
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207 mg (74 %) as Tan colored solid; 1H NMR (400 MHz, DMSO-d6); 8.40 (s, 1H), 8.35-8.33 
(d, J=8Hz, 1H), 8.06 (s, 1H), 7.83-7.81 (d, J=8Hz, 1H), 7.58-7.51 (m, J=8Hz, 4H), 7.48-7.42 
(m, 1H),  5.94 (s, 2H), 2.61 (s, 3H); 13C NMR (100 MHz, DMSO-d6); 198.0, 140.7, 140.8, 
136.0, 135.2, 131.4, 129.8, 127.4 , 125.6, 121.3, 119.9, 112.1, 110.8, 43.8, 27.3; LCMS 
(MM:ES+APCI) 402.2 (M+H)+; Anal. Calcd for C21H14Cl3NO: C, 62.63; H, 3.50; N, 3.48;  
Found: C, 62.64; H, 3.50; N, 3.48. 
1-(6-chloro-9-(4-iodobenzyl)-9H-carbazol-3-yl)ethanone (3c)  
217 mg (68 %) as pale yellow colored solid; 1H NMR (400 MHz, DMSO-d6); (
1H NMR (400 
MHz, DMSO-d6); 8.41 (s, 1H) , 8.37-8.35 (d, J=8Hz, 1H), 8.26 (s, 1H), 7.87-7.85 (d, J=8Hz, 
1H), 7.69-7.63 (m , 3H), 7.54-7.52 (d, J=8Hz, 1H), 6.94-6.92 (m, 2H),  5.77 (s, 2H), 2.68 (s, 
3H); 13C NMR (100 MHz, DMSO-d6); 198.3, 140.6, 140.4, 137.8, 137.6, 135.6, 129.3, 127.5, 
125.4, 124.6, 123.2, 121.4, 120.0, 112.0, 110.6, 93.7, 45.7, 27.5; HRMS Calcd 481.9779; 
Found: 481.9781(M+Na+).   
1-(6-chloro-9-ethyl-9H-carbazol-3-yl)ethanone (3d) 
153 mg (79 %) as off-white colored solid; 1H NMR (400 MHz, DMSO-d6); 8.32 (s, 1H), 
8.29-8.27 (d, J=8Hz, 1H), 8.09 (s, 1H), 7.80-7.78 (m, 1H), 7.58-7.56 (d, J=8Hz, 1H), 7.48-
7.45 (m, 1H), 4.21-4.18 (m,  2H), 2.64 (s,  3H), 1.24-1.22 (m, 3H); 13C NMR (100 MHz, 
DMSO-d6); 197.5, 140.5, 139.1, 136.6, 126.2, 125.5, 123.8, 123.2, 121.2, 120.9, 119.3, 
113.4, 111.9, 42.3, 26.4, 14.1; HRMS Calcd 294.0656; Found: 294.0658 (M+Na 
3'-((3-acetyl-6-chloro-9H-carbazol-9-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile (3e, ACB)   
243 mg (78 %) as pale yellow colored solid; 1H NMR (400 MHz, DMSO-d6); 8.43 (s, 1H), 
8.39-8.37 (d, J=8Hz, 1H), 8.34 (s, 1H), 7.92-7.86 (m, 2H), 7.77-7.72 (m, 2H), 7.56-7.48 (m, 
5H), 7.28-7.26 (d, J=8Hz, 2H), 5.90 (s, 2H), 2.68 (s, 3H); 13C NMR (100 MHz, DMSO-d6); 
198.3, 140.6, 140.4, 140.4, 135.6, 133.7, 131.1, 127.8, 127.6, 126.9, 125.6, 125.4, 124.7, 
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123.2, 121.4, 120.1, 112.0, 110.5, 45.5, 27.5; HRMS Calcd 457.1078; Found: 457.1079 
(M+Na+).   
9-benzyl-3-chloro-6-ethyl-9H-carbazole (3f)    
190 mg (79 %) as white colored solid; 1H NMR (400 MHz, DMSO-d6) 8.25 (s, 1H), 8.18- 
8.16 (d, J=8Hz, 1H), 8.06 (s, 1H), 7.78-7.76 (d, J=8.0Hz, 1H), 7.62-7.60 (d, J=8Hz, 1H), 
7.46-7.43 (m, 1H), 7.27-7.15 (m, 4H) , 6.91-6.90 (m, 1H), 5.73 ( s, 2H), 2.78-2.73 (m, 2H), 
1.28-1.24 (t, 3H);  13C NMR (100 MHz, DMSO-d6); 141.8, 140.0, 138.0, 137.3, 129.0, 128.0, 
127.1, 126.1, 124.4, 123.5, 122.0, 120.8, 120.5, 118.9, 111.7, 108.9, 46.1, 24.3, 13.9; LCMS 
(MM:ES+APCI) 320.2(M+H)+; Anal. Calcd for C21H18ClN : C, 78.86; H, 5.67; N, 4.38;  
Found: C, 78.88; H, 5.68; N, 4.39. 
3-chloro-9-(2,6-dichlorobenzyl)-6-ethyl-9H-carbazole (3g) 
 202 mg (71 %) as off-white colored solid; 1H NMR (400 MHz, DMSO-d6); 8.20 (s, 1H) , 
8.09-8.07 (d, J=8Hz, 1H), 7.57-7.55 (d, J=8Hz, 2H), 7.46-7.39 (m, 3H), 7.22 (s, 1H), 7.07-
7.05 (d, J=8Hz, 1H),  5.81 (s, 2H), 2.78-2.71 (m, 2H), 1.20-1.17 (t, 3H); 13C NMR (100 MHz, 
DMSO-d6); 142.8, 141.1, 140.0, 137.6, 133.4, 132.3, 132.1, 129.1, 128.7, 123.1, 120.8, 
117.4, 113.1, 110.8, 45.6, 24.7, 14.9; HRMS Calcd 410.0241; Found: 410.0242 (M+Na+).   
3-chloro-6-ethyl-9-(4-iodobenzyl)-9H-carbazole (3h)  
232 mg (69 %) as white colored solid; 1H NMR (400 MHz, DMSO-d6); 8.23 (s, 1H), 8.13-
8.11 (d, J=8Hz, 1H), 7.64-7.62 (d, J=8Hz, 2H), 7.58-7.56 (d, J=8Hz, 1H), 7.46 (s, 1H), 7.40-
7.38 (m, 1H), 7.12-7.10 (d, J=8Hz, 1H), 6.94-6.92 (d, J=8Hz, 2H),   5.62 (s, 2H), 2.79-2.73 
(m, 2H), 1.27-1.23 (t , 3H); 13C NMR (100 MHz, DMSO-d6); 143.6, 140.3, 137.5, 137.5, 
133.1, 132.4, 131.9, 129.1, 128.6, 128.1, 123.3, 122.4, 120.1, 118.4, 111.3, 108.1, 91.2, 46.7, 
25.6, 14.2; HRMS Calcd 467.9986; Found: 467.9987 (M+Na+).    
3-chloro-6,9-diethyl-9H-carbazole (3i) 
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151 mg (78 %) as white colored solid; 1H NMR (400 MHz, DMSO-d6) 8.00 (s, 1H), 7.83-
7.81 (d, J=8Hz, 1H), 7.62 (s, 1H), 7.52-7.50 (d, J=8Hz, 1H), 7.39-7.31 (m, 2H), 4.26-4.14 (m, 
2H), 2.57-2.55(m, 2H), 1.30-1.20 (m, 6H); 13C NMR (100 MHz, DMSO-d6); 142.0, 141.4, 
137.7, 132.2, 127.2, 125.6, 123.4, 121.7, 118.9, 114.4, 113.8, 110.6, 23.2, 13.1, 12.8; HRMS 
Calcd 280.0863; Found: 280.0865 (M+Na+).   
3'-((3-chloro-6-ethyl-9H-carbazol-9-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile (3j)   
244 mg (77 %) as off-white  colored solid; 1H NMR (400 MHz, DMSO-d6) 8.09 (s, 1H), 
7.94-7.92 (d, J=8Hz, 1H), 7.81-7.79 (d, J=8Hz, 1H), 7.68-7.65 (m, 1H), 7.55-7.52 (m, 2H), 
7.30-7.26 (m, 2H), 7.19-7.03 (m, 6H),  5.85 (s, 2H), 2.80-2.70 (m, 2H), 1.3-1.2 (m, 3H); 13C 
NMR (100 MHz, DMSO-d6); 142.9, 140.0, 137.4, 136.0, 134.8, 132.2, 130.2, 129.1, 127.1, 
125.6, 123.3, 121.0, 120.8, 116.1, 113.8, 110.6, 48.1, 25.1, 14.1; HRMS Calcd 443.1285; 
Found: 443.1286 (M+Na+).  
1-(9-benzyl-6-chloro-9H-carbazol-3-yl)ethanol (3k)   
188 mg (79 %) as off-white colored solid; 1H NMR (400 MHz, DMSO-d6); 8.25 (s, 1H) , 
8.16-8.14 (d, J=8Hz, 1H), 7.70-7.58 (m, 5H), 7.41-7.39 (d, J=8Hz, 1H), 7.24-7.22 (d, J=8Hz, 
1H), 6.93-6.91 (d, J=8Hz, 2H),  5.66 (s, 2H), 5.25 (s, 1H), 4.88-4.86 (m, 1H), 1.39-1.37 (d, 
J=8Hz, 3H); 13C NMR (100 MHz, DMSO-d6); 143.0, 140.8, 139.5, 138.0, 137.3, 129.0, 
128.0, 127.5, 126.1, 124.9, 123.5, 121.1, 120.5, 120.2, 119.0, 110.9, 109.2, 69.8, 46.2, 25.5; 
HRMS Calcd 358.0969; Found: 358.0970 (M+Na+).  
1-(6-chloro-9-(2,6-dichlorobenzyl)-9H-carbazol-3-yl)ethanol (3l)  
207 mg (72 %) as off-white colored solid; 1H NMR (400 MHz, DMSO-d6); 8.21 (s, 1H), 
8.12-8.10 (d, J=8Hz, 1H), 7.56-7.54 (d, 2H), 7.47-7.38 (m, 4H), 7.21-7.19 (d, J=8Hz, 1H),  
5.82 (s, 2H), 5.20 (s, 1H), 4.81-4.78 (m, 1H), 1.33-1.31 (d, J=8Hz, 3H); 13C NMR (100 MHz, 
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DMSO-d6); 141.8, 140.8, 138.0, 137.7, 135.4, 128.9, 127.5, 125.4, 124.1, 123.6, 120.9, 
120.0, 112.0, 110.1, 68.7, 45.4, 27.0; HRMS Calcd 426.0190; Found: 426.0192 (M+Na+).   
1-(6-chloro-9-(4-iodobenzyl)-9H-carbazol-3-yl)ethanol (3m) 
230 mg (70 %) as white colored solid; 1H NMR (400 MHz, DMSO-d6); 8.24 (s, 1H), 8.16-
8.14 (d, J=8Hz, 1H), 7.64- 7.58 (m, 4H), 7.41- 7.39 (d, J=8.0Hz, 1H), 7.24-7.22 (d, J=8Hz, 
1H), 6.93-6.90 (m, 2H), 5.63 (s, 2H), 5.25 (m, 1H), 4.88-4.85 (m, 1H), 1.39-1.37 (d, J=8Hz, 
3H); 13C NMR (100 MHz, DMSO-d6); 147.3, 141.2, 139.1, 137.9, 137.8, 129.3, 125.6, 124.1, 
123.9, 120.9, 120.5, 120.2, 117.9, 111.4, 106.6, 93.6, 69.0, 45.5, 26.7; HRMS Calcd 
483.9936; Found: 483.9937 (M+Na+).   
1-(6-chloro-9-ethyl-9H-carbazol-3-yl)ethanol (3n) 
143 mg (74 %) as off-white colored solid; 1H NMR (400 MHz, DMSO-d6) 8.23 (s,1H), 8.15-
8.13 (d, J=8Hz, 1H), 7.65-7.59 (m,2H), 7.42-7.38 (m, 1H), 7.25-7.23 (d, J=8Hz, 1H), 5.65 (s, 
2H), 5.16 (s, 1H), 4.87-4.86 (m, 1H), 1.35-1.33 (m, 3H), 1.24-1.22 (m, 3H); 13C NMR (100 
MHz, DMSO-d6); 143.0, 141.1, 136.3, 134.3, 131.1, 129.0, 128.7, 128.2, 126.0, 125.5, 124.8, 
119.4, 109.6, 68.3, 45.4, 27.8, 14.3; HRMS Calcd 296.0813; Found: 296.0814 (M+Na+).   
3'-((3-chloro-6-(1-hydroxyethyl)-9H-carbazol-9-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile 
(3o) 
239 mg (77 %) as off-white colored solid; 1H NMR (400 MHz, DMSO-d6) 8.23 (s, 1H), 8.18- 
8.16 (d, J=8Hz, 1H), 8.13 (s,1H), 7.89-7.85 (m,2H), 7.77-7.72 (m, 2H), 7.56-7.48 (m, 5H), 
7.28-7-25 (m, 2H), 5.92 (s,2H), 5.29-5.28 (m, 1H), 4.85-4.79 (m, 1H), 1.33-1.30 (d, 3H); 13C 
NMR (100 MHz, DMSO-d6); 142.5, 141.4, 140.6, 136.5, 134.02, 130.9, 127.9, 127.5, 126.0, 
125.4, 124.7, 122.9, 121.5, 120.1, 111.9, 110.6, 70.0, 46.5, 27.2 LCMS (MM:ES+APCI) 
437.4 (M+H)+; Anal.Calcd for C28H21ClN2O: C, 76.97; H, 4.84; N, 6.41;  Found: C, 76.99; H, 
4.86; N, 6.43. 
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Pharmacology 
MTT assay 
The antiproliferative effect of the compounds synthesized against A549 and LLC cells was 
determined by the MTT dye uptake method as described previously.34, 35 Briefly, cancer cells 
(2.5x104/ml) were incubated in triplicate in a 96-well plate, in the presence of varying 
compound concentrations at a volume of 0.2 ml, for different time intervals at 37 °C. 
Thereafter, 20 µl MTT solution (5 mg/ml in PBS) was added to each well. After 2 h 
incubation at 37 °C, a 0.1 ml lysis buffer (20% SDS, 50% dimethylformamide) was added; 
incubation was performed for 1 h at 37 °C, and the optical density (OD) at 570 nm was 
measured by plate reader. 
Western blotting 
Western blotting analysis was performed as described earlier.36, 37 For detection of phospho-
proteins, ACB treated whole-cell extracts were lysed in lysis buffer (20 mM Tris (pH 7.4), 
250 mM NaCl, 2 mM EDTA (pH 8.0), 0.1% Triton X-100, 0.01 mg/ml aprotinin, 0.005 
mg/ml leupeptin, 0.4 mM PMSF, and 4 mM NaVO4). Lysates were then spun at 14,000 rpm 
for 10 min to remove insoluble material and resolved on SDS gel. After electrophoresis, the 
proteins were electrotransferred to a nitrocellulose membrane, blocked with 5% non-fat milk, 
and probed with anti-phospho-STAT3/STAT3 antibodies (1:1000) overnight at 4°C. The blot 
was washed, exposed to HRP-conjugated secondary antibodies for 1 h, and finally examined 
by chemiluminescence. 
Molecular docking analysis 
We followed a dual strategy to analyze structure-activity relationships (SAR) of the 15 
carbazole compounds. We performed a ligand-based analysis of SAR trends for carbazole 
core substituents (R groups) as well as N-substitutions (R1 groups) inspired by matched 
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molecular pair analysis.38 We extracted matching substituents and identified enriched 
chemical groups amongst compounds of higher activity. 
On the other hand, we attempted to rationalize the SAR trends by docking the carbazole 
compounds to the SH2 domain of STAT3. Therefore, we extracted the SH2 domain from the 
crystal structure of the STAT3 homo-dimer (PDB: 1BG1)39 and prepared the structure for 
docking using protonate3D as implemented in Molecular Operating Environment (MOE, 
version 2014.0901).40 Since the pTyr binding site has been described as a hot-spot for small 
molecule binding,41 we chose the pTyr as center for in silico docking experiments. We 
deleted bound protein residues in that region and docked the carbazole series after 
establishing successful redocking of pTyr with an RMSD < 2Å using MOE's default settings.  
Resulting docking poses were visualized using PyMOL (Schrodinger LLC, version 1.6.0.0). 
Results and Discussion 
Chemistry  
We achieved the synthesis of substrate 1-(2'-amino-5',6-dichloro-[1,1'-biphenyl]-3-
yl)ethanone (1a), by the Suzuki coupling reaction as recently developed in our laboratory 
from commercially available (2-(2-amino-5-chlorophenyl)-4,5,5-trimethyl-1,3,2-
dioxaborolan-4-yl)methylium and 1-(3-bromo-4-chlorophenyl) ethanone.42 The resulting 
product (1a) was readily reduced to corresponding 2',5-dichloro-5'-ethyl-[1,1'-biphenyl]-2-
amine (1b) and 1-(2'-amino-5',6-dichloro-[1,1'-biphenyl]-3-yl)ethanol (1c) as depicted in 
Scheme 1 (i, ii, iii).  
In the next step, we developed an efficient protocol for the direct one-pot synthesis of 
N-substituted carbazoles via N-alkylation followed by C-N bond forming coupling reaction 
using Cu catalyst in the presence of various ligands. The conversion of substrate 1-(2'-amino-
5',6-dichloro-[1,1'-biphenyl]-3-yl)ethanone (1a) to the corresponding N-substituted carbazole 
derivative 1-(9-benzyl-6-chloro-9H-carbazol-3-yl)ethanone (3a) was carried out by treating 
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1a with benzylbromide (2a), Cu  catalyst and a base (Scheme 2 and Table 1). The preliminary 
analysis suggested that the use of combination of 8 mol% Cu2O and 10 mol% N,N’-
dimethylethane-1,2-diamine (DMEDA) in presence of K2CO3 at 150 ºC in DMF resulted in 
efficient conversion to 3a. We observed the incomplete conversion when 5mol% Cu2O was 
used despite of longer reaction time and high temperature. Interestingly, it was found that 
nano Cu2O accelerated the reaction with lesser reaction time and better yield (Table 1, entry 
12) which can be attributed to availability of large surface area for reaction.  
We observed no reaction in the absence of the ligand (Table 1, entry 13) whereas, the use of 
bidentate ligands such as 1,10-phenanthroline, Xantphos and Ethylene diamine resulted in the 
good yield of the product (Table 1, entry 14-16). These results encouraged us to examine the 
generality of one-pot method for the synthesis of series of novel N-substituted carbazoles 
(Scheme 1, iv). This protocol was applied successfully on carbonyl (1a), alkane (1b) and 
hydroxyl (1c) substituents with reasonable yields as shown in table 2.   
Mechanism  
On the basis of previous mechanistic studies in copper catalyzed intramolecular C-N bond 
formation,43 we propose the possible concerted mechanism for the conversion of 2-amino-2’-
chloro biphenyls to N-substituted carbazoles as shown in Scheme 3. 
As it is clear from the Scheme-3 that initially a Cu–L complex was formed which in turn 
coordinates with secondary amine by intramolecular oxidative addition to form complex A. 
The complex A further reacts with base to form Cu-N bond to form complex B. Reductive 
elimination step regenerates the copper catalyst and formation of the desired product C. Our 
findings suggested that secondary amines were more liable for cyclisation compare to 
primary amines 25, 44 wherein poor ring formation was observed in the reaction carried out 
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without using benzylbromide (2a) (Scheme 2), which apparently support N-benzylation 
occurs before the coordination of the copper complex with amine nitrogen.  
Carbazole derivatives suppresses the proliferation of A549 and LLC cells 
We evaluated all the synthesized carbazole derivatives for their antiproliferative activity 
against A549 and LLC cells. Among the tested carbazoles, compounds 3e (ACB) and 3j 
showed significant antiproliferative effect (IC50 < 20 µM) against A549 & LLC cells.  ACB 
was identified as the lead compound with IC50 of 13.6 and 16.4 µM against A549 and LLC 
cells respectively. Paclitaxel was used as the positive control which displayed the IC50 of 
0.0044 µM against A549 cells. 
ACB downregulates the constitutive STAT3 phosphorylation in lung cancer cells 
Phosphorylation of STAT3 at Y705 causes the dimerization and translocation into nucleus to 
relay the oncogenic signals by expressing the genes involved in proliferation, antiapoptosis, 
angiogenesis and tumor evasion.5 Carbazoles are known for their inhibitory activity against 
the phosphorylation of STAT3 (Tyr-705), in turn inducing the antiproliferative effect in 
cancer cells.24 Therefore, we treated A549, HCC-2279 and H1975 cells with 10 µM of ACB 
for 6 h and investigated the effect of lead compound on the persistent activation of STAT3 by 
western blot analysis using antibodies which recognize phosphorylation of STAT3 at Tyr-
705. ACB significantly downregulated the STAT3 phosphorylation in all the tested cell lines 
(Figure 1A). The levels of total STAT3 and β-actin remain unchanged indicating the 
inhibitory efficacy of carbazoles on STAT3 phosphorylation. 
Given the role of STAT3 phosphorylation in translocation to nucleus and DNA binding, we 
further investigated the levels of phospho-STAT3 and lysine demethylase (LSD1) in the 
nuclear extract of HCC-2279 cells treated with different doses of ACB (0, 1.25, 2.5, 5, 10, 20, 
40 and 80 µM). ACB downregulated the nuclear pool of phospho-STAT3 indicating that 
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ACB inhibits the phosphorylation of STAT3, thereby translocation into nucleus and in turn 
reduces its DNA binding ability (Figure 1B). LSD1 was used as nuclear marker and loading 
control for nuclear protein. The levels of LSD1, cytoplasmic STAT3 and β-actin remain 
unchanged. 
In silico interaction studies of carbazoles that targets STAT3 in lung cancer cells.  
Matched pair analysis identified the acetyl group on the core carbazole as most promising 
substituent at the R position. In four of five matched molecular series, the acetyl group is 
associated with highest cellular activities. An ethyl substituent is associated with poor 
solubility of the corresponding compounds, especially in connection with chlorine 
substitutions on the R1 group. On the other hand, we investigated N-substituents (R1 position) 
and found the 3-(2-cyano-phenyl)-benzyl substitution as decoration with highest activity in 
two out of three matched molecular series. Thus, ACB represents the optimum candidate 
molecule for further development from a matched pairs perspective.  
On the other hand, we attempted to rationalize the SAR trends by docking the carbazoles to 
the SH2 domain of STAT3. Therefore, we extracted the SH2 domain from the crystal 
structure of the STAT3 homo-dimer (PDB: 1BG1)39 and chose the pTyr as center for in silico 
docking experiments. Interestingly, the 3-(2-cyano-phenyl)-benzyl substituted compounds 
such as ACB, 3j and 3o showed distinct behavior in molecular docking apart from conserved 
shape fit and hydrophobic interactions. In general, the R groups are buried in the pTyr 
binding site and thereby form hydrogen bonds via the acetyl and hydroxyethyl group (see 
Figure 2). This explains, the higher activity of acetyl and ethyl decoration over ethyl which 
lacks the acceptor functionality resembling the pTyr in binding to the side-chain of Arg-609. 
Here, 3-(2-cyano-phenyl)-benzyl substituted compounds are predicted to interact with Arg-
609 and Ser-613 in the pTyr site via the cyano group. This also leads to a change in the SAR 
for this particular series as expected after a reorientation of the binding mode.45 Since the 
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cyano groups replaces the R-group, the SAR for R substitutions is flatter and shows little 
activity difference for acetyl (3'-((3-acetyl-6-chloro-9H-carbazol-9-yl)methyl)-[1,1'-
biphenyl]-2-carbonitrile (ACB), hydroxyethyl (compound 3o), and ethyl decoration 
(compound 3j). 
Conclusion 
STAT3 is identified as one of the attractive molecular therapeutic targets for the designing of 
small molecule inhibitors because of its persistent activation in more than 20 types of cancers 
including various solid and liquid tumors. We therefore for the first time implemented the 
one-pot synthesis of carbazole derivatives using nano-cuprous oxide as a catalyst via 
intramolecular C-N bond forming reactions. Initial investigation on the antiproliferative 
activity of carbazoles on lung cancer cells projected ACB as the lead structure. Further 
examination revealed that, ACB suppresses the phosphorylation of STAT3 thereby 
interfering with its transcriptional activity. Analysis of phospho-STAT3 in whole-cell and 
nuclear extracts clearly demonstrated the mechanism of action of ACB. The results of the 
STAT3 inhibition readout are closely correlated with antiproliferative activity of ACB. In 
silico analysis substantially supported our in vitro experimental evidences. Previous reports 
have suggested that, carbazole inhibits STAT3 phosphorylation by modulating protein-
tyrosine phosphatase PTPN6 and it requires further investigation to explore the possible 
involvement of phosphatases in ACB mediated STAT3 inhibition in lung cancer cells. 
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Figure Legends 
Scheme 1: Schematic representation for the preparation of title compounds. i) SCS-Bi2O3, 
Pd(pdppf)Cl2, Water, 110 ºC, TBAB; ii) NaBH4/BF3ethyl etharate, THF, 12 h; iii) 
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NaBH4/NaOH, Ethanol, Reflux, 10 h; iv) R
1Br (2a-e), K2CO3/Nano Cu2O(8mol%)/DMEDA, 
DMF/ 150 ºC,15 h; R = COCH3, CH2CH3, CHOHCH3; R
1= benzyl, 2,6-Dichlorobenzyl,  4-
Iodobenzyl,  Bromo ethane, 4-bromomethyl-2-cyanobiphenyl. 
Scheme 2: Schematic representation of synthesis of 1,9-substituted-6-chlorocarbazoles via N-
alkylation followed by C-N bond forming coupling reaction  using Cu catalyst in presence of 
ligand. 
Scheme 3: Possible concerted mechanism for the conversion of 2-amino-2’-chloro biphenyls 
to 1,9-substituted-6-chlorocarbazole. 
Figure 1: ACB downregulates phospho-STAT3 in lung cancer cells. A) A549, HCC-2279 
and H1975 cells (5 × 105 /ml) were treated with the indicated concentrations (0, 1.25, 2.5, 5, 
10, 20, 40 and 80 µM) of ACB for 6 h, after which whole-cell extract was prepared and 
resolved on SDS-polyacrylamide gel, electrotransferred onto nitrocellulose membrane, and 
probed for phospho-STAT3, and the same blot was stripped and reprobed with STAT3 
antibody to verify equal protein loading. B) HCC-2279 cells were treated with different doses 
of ACB (0, 1.25, 2.5, 5, 10, 20, 40 and 80 µM) and nuclear and cytoplasmic extract was 
prepared. Nuclear extract was resolved on SDS-polyacrylamide gel, electrotransferred onto 
nitrocellulose membrane, and probed for phospho-STAT3 and LSD1. Cytoplasmic extract 
was also resolved on SDS-polyacrylamide gel, electrotransferred onto nitrocellulose 
membrane, and probed for STAT3 and β-actin antibody to verify equal protein loading. 
Figure 2: Molecular docking of carbazole compounds to the STAT3 SH2 domain: A) The 
binding site of pTyr-705 (sticks in elemental colors, carbon in white) in the SH2 domain 
(PDB: 1BG1) is associated with polar interactions with Ser-613 and Arg-609 (both shown as 
lines). B) Compound 3c is predicted to position the acetyl function in the pTyr site forming 
hydrogen bonding to Arg-609. C) ACB shows a switch in binding mode compared to 
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compound 3c and places a cyano function in the pTyr site. In both binding modes carbazole 
show shape complementarity to the binding site and form Van der Waals contacts to the 
peptide binding groove.                                                                             
 
Table 1 
Entry 8mol% 
Catayst 
Ligand Base Temp/Tim
e 
Yield
a
 
1 CuO DMEDA KO’Bu 150OC /20h 31% 
2 Cu(OAc)2 DMEDA KO’Bu 150
OC/ 20h NR 
3 CuI DMEDA KO’Bu 150OC/ 20h NR 
4 Cu2O DMEDA KO’Bu 150
OC /20h 47% 
5 Nano CuO DMEDA KO’Bu 150OC /20h 42% 
6 Nano Cu2O DMEDA KO’Bu 150
OC /20h 56% 
7 CuO DMEDA K2CO3 150
OC/ 20h 32% 
8 Cu(OAc)2 DMEDA K2CO3 150
OC /20h NR 
9 CuI DMEDA K2CO3 150
OC /20h NR 
10 Cu2O DMEDA K2CO3 150
OC /20h 55% 
11 Nano CuO DMEDA K2CO3 150
OC /20h 43% 
12 Nano Cu2O DMEDA K2CO3 150
OC/ 15h 79% 
13 Nano Cu2O ---- K2CO3 150
OC/ 15h NR 
14 Nano Cu2O 1,10 
phenanthroli
ne 
K2CO3 150
OC/ 15h 79% 
15 Nano Cu2O Xantphos K2CO3 150
OC/ 15h 74% 
16 Nano Cu2O Ethylenedia
mine 
K2CO3 150
OC/ 15h 71% 
a
The reaction was carried out in DMF solvent 
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Table 2: The physical parameters of the synthesized heterocyclic compounds a 
Entry Amines 
Alkyl 
Halides 
Productc 
Yieldb 
(%) 
 
M.P 
(ºC) 
IC50 (µM) 
 
A549 LLC 
3a 
Cl
NH2
Cl
O
 
 
 
 
79 
 
 
118-119 
 
38.2 ± 2.7 
 
35.2±4.3 
3b 
  
 
 
 
74 
 
 
 
185-186 
 
 
17.4 ± 0.1 
 
 
19.1 ± 0.2 
3c 
 
 
 
68 
 
 
162-163 
 
18.2 ± 2.7 
 
21.6 ± 4.2 
3d 
 
  
 
 
79 
 
 
122-123 
 
22.1 ± 2.2 
 
24.7 ± 3.1 
3e  
  
78 
 
144-145 
 
13.6 ± 1.1 
 
16.4 ± 2.3 
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3f 
 
 
 
79 
 
 
124-125 
 
 
48 ± 4.1 
 
 
>50 
3g 
 
 
71 
 
165-166 
 
>50 
 
>50 
3h 
  
69 
 
143-144 
 
>50 
 
>50 
3i  
 
78 
 
128-129 
 
>50 
 
>50 
3j 
  
77 
 
140-141 
 
17.2 ± 1.3 
 
 
19.2 ± 2.7 
3k 
 
 
 
79 
 
125-126 
 
23.1 ± 4.1 
 
22.1 ± 1.3 
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 3l 
 
 
72 
 
141-142 
 
35.6± 3.6 
 
32.4 ± 2.1 
3m 
 
 
70 
 
119-120 
 
26.4 ± 1.7 
 
38.2 ± 3.2 
3n  
N
Cl
HO
 
74 
 
116-117 
 
>50 
 
>50 
3o 
  
77 
 
132-133 
 
18.6 ± 1.8 
 
21.7 ± 2.7 
aReaction condition:  K2CO3/Nano Cu2O (8mol%)/DMEDA, DMF/ 150 ºC, 15 h; 
bIsolated yields; cAll the 
synthesized compounds exhibited spectral properties consistent with the assigned structures and were fully 
characterized by their spectroscopic data (1H, IR, LC MS, elemental and 13C NMR, HRMS analysis). 
Page 23 of 28 RSC Advances
R
S
C
A
dv
an
ce
s
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
29
 M
ar
ch
 2
01
6.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 at
 B
uf
fa
lo
 L
ib
ra
rie
s o
n 
05
/0
4/
20
16
 0
5:
41
:0
0.
 
View Article Online
DOI: 10.1039/C6RA01906D
  
 
 
Schematic representation for the preparation of title compounds. i) SCS-Bi2O3, Pd(pdppf)Cl2, Water, 110 
ºC, TBAB; ii) NaBH4/BF3ethyl etharate, THF, 12 h; iii) NaBH4/NaOH, Ethanol, Reflux, 10 h; iv) R1Br (2a-e), 
K2CO3/Nano Cu2O(8mol%)/DMEDA, DMF/ 150 ºC,15 h; R = COCH3, CH2CH3, CHOHCH3; R1= benzyl, 2,6-
Dichlorobenzyl,  4-Iodobenzyl,  Bromo ethane, 4-bromomethyl-2-cyanobiphenyl.  
28x20mm (300 x 300 DPI)  
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Possible concerted mechanism for the conversion of 2-amino-2’-chloro biphenyls to 1,9-substituted-6-
chlorocarbazole  
28x30mm (300 x 300 DPI)  
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ACB downregulates phospho-STAT3 in lung cancer cells. A) A549, HCC-2279 and H1975 cells (5 × 105 /ml) 
were treated with the indicated concentrations (0, 1.25, 2.5, 5, 10, 20, 40 and 80 µM) of ACB for 6 h, after 
which whole-cell extract was prepared and resolved on SDS-polyacrylamide gel, electrotransferred onto 
nitrocellulose membrane, and probed for phospho-STAT3, and the same blot was stripped and reprobed with 
STAT3 antibody to verify equal protein loading. B) HCC-2279 cells were treated with different doses of ACB 
(0, 1.25, 2.5, 5, 10, 20, 40 and 80 µM) and nuclear and cytoplasmic extract was prepared. Nuclear extract 
was resolved on SDS-polyacrylamide gel, electrotransferred onto nitrocellulose membrane, and probed for 
phospho-STAT3 and LSD1. Cytoplasmic extract was also resolved on SDS-polyacrylamide gel, 
electrotransferred onto nitrocellulose membrane, and probed for STAT3 and β-actin antibody to verify equal 
protein loading.  
32x26mm (300 x 300 DPI)  
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Molecular docking of carbazole compounds to the STAT3 SH2 domain: A) The binding site of pTyr-705 
(sticks in elemental colors, carbon in white) in the SH2 domain (PDB: 1BG1) is associated with polar 
interactions with Ser-613 and Arg-609 (both shown as lines). B) Compound 3c is predicted to position the 
acetyl function in the pTyr site forming hydrogen bonding to Arg-609. C) ACB shows a switch in binding 
mode compared to compound 3c and places a cyano function in the pTyr site. In both binding modes 
carbazole show shape complementarity to the binding site and form Van der Waals contacts to the peptide 
binding groove.  
16x6mm (300 x 300 DPI)  
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